RNTX Stock Forecast: Rein Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.37
+3.58% on the day

The median 12-month analyst price target for Rein Therapeutics, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$31.7M
Ticker Nerd rank
39/ 100
Median analyst target
$6.00
Analysts covering
2
Revenue$0.0
Operating income−$6.1M
Net income−$6.4M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−34.3%
1M
−33.4%
YTD
−68.3%
1Y
−70.8%
From 52W high
−80.4%
From 52W low
+3.6%
$0.36
$1.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Rein Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
72
Revisions
67
Growth
64
Value
31
Quality
26
Issuance
22
Volatility
19
Momentum
15

Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RNTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26RNTXHigh $8.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$4.00
Low
$6.00
Median
$8.00
High
Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
18 Nov 2026HC Wainwright & Co.ReiteratesBuy$8.00
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$8.00
20 July 2026Maxim GroupInitiatesBuy$4.00
1 June 2026HC Wainwright & Co.MaintainsBuy$10 → $8.00
21 Jan 2026Brookline CapitalDowngradeHold—
22 Sept 2025HC Wainwright & Co.InitiatesBuy—
19 Aug 2025Brookline CapitalDowngradeHold—
18 Apr 2024Ladenburg ThalmannMaintainsBuy$9.00 → $19
1 Dec 2023Ladenburg ThalmannUpgradeBuy$9.00
30 June 2022HC Wainwright & Co.MaintainsBuy$2.00 → $1.00
29 June 2022William BlairDowngradeMarket Perform—
5 June 2020HC Wainwright & Co.MaintainsBuy$3.00 → $2.00
31 Mar 2020H.C. WainwrightMaintainsBuy—
31 Mar 2020HC Wainwright & Co.MaintainsBuy$6.00 → $3.00
9 Apr 2019Canaccord GenuityMaintainsBuy$19 → $5.00
11 Mar 2019H.C. WainwrightInitiatesBuy—
24 July 2017Bank of AmericaInitiatesBuy—
24 July 2017Canaccord GenuityInitiatesBuy—
24 July 2017JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNTX.

Market Radar

This page is one stock. Monday covers all of them.

RNTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RNTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Rein Therapeutics, Inc. returned −70.8% against +9.2% for the S&P 500, dividends included.

RNTX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140160Jan 26Apr 26Jul 26Oct 26RNTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.9×

Cheaper than 24% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−100.5%

Higher than 13% of US stocks

Return on assets
−24.6%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rein Therapeutics, Inc. has a market value of $31.7M and an enterprise value of $41.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$49.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$18.8M.

  • Shares outstanding: 85.5M.

  • Rein Therapeutics, Inc. employs 10 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

RNTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNTXRein Therapeutics, Inc.$31.7M39
NNVCNanoViricides, Inc.$29.0M52
SERSerina Therapeutics, Inc.$28.4M18
PMNProMIS Neurosciences, Inc.$28.3M30
NXTCNextCure, Inc.$29.5M43
CRBUCaribou Biosciences, Inc.$30.5M43
EDSAEdesa Biotech, Inc.$27.0M49

Take a look at RNTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Rein Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RNTX

What is the RNTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Rein Therapeutics, Inc. is $6, with estimates ranging from $4 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNTX stock a buy right now?

Of the 2 analysts covering Rein Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rein Therapeutics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNTX?

As at 21 Nov 2026, Rein Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).

Will RNTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $6, and Ticker Nerd's factor model ranks Rein Therapeutics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNTX stock forecast for 2030?

No analyst covering Rein Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $8 over the next 12 months.

How has RNTX stock performed over the past year?

Rein Therapeutics, Inc. returned -70.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rein Therapeutics, Inc. do?

Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion.

Company

About Rein Therapeutics, Inc.

Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for orphan pulmonary and fibrosis indications. The company’s current pipeline centers on LTI-03, a peptide being advanced for idiopathic pulmonary fibrosis, and LTI-01, a therapy candidate for loculated pleural effusion. Its portfolio also includes additional preclinical programs targeting fibrosis-related pathways and cystic fibrosis. Rein Therapeutics develops peptide-based and protein-based therapeutics designed to address serious diseases with limited treatment options, making it a specialized player in respiratory and fibrotic medicine. Headquartered in Austin, Texas, Rein Therapeutics serves the biopharmaceutical market through research, clinical development, and product advancement for highly targeted rare-disease applications.

CEO Dr. James Brian Windsor Ph.D. · 10 employees · United States · https://www.reintx.com